Alessandro Cavaliere
University of Verona
CancerInternal medicineOncologyPerformance statusPancreatic cancerGemcitabineIrinotecanFluorouracilOxaliplatinAdenocarcinomaKRASPopulation2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)University hospitalIn patientPatient perceptionsHealth professionalsCancer researchFamily medicineInterleukin 8MedicineCohort
Publications 15
#1Giulia Orsi (UniSR: Vita-Salute San Raffaele University)H-Index: 10
#2M. Di Marco (UNIBO: University of Bologna)H-Index: 3
Last. Giampaolo Tortora (UCSC: Catholic University of the Sacred Heart)H-Index: 16
view all 30 authors...
Background null Germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-related pancreatic ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents. This study aimed at exploring safety profile, dose intensity, and activity of different chemotherapy regimens in this setting. null Patients and methods null gBRCA1-2pv PDAC patients of any age and clinical tumor stage who completed a first course of chemotherapy were eligible. A descriptive analysis of chemotherapy toxicity, ...
#1Davide MelisiH-Index: 32
Last. Giovanni ButturiniH-Index: 51
view all 21 authors...
Abstract Background Pancreaticoduodenal cancer (PDC) is a group of malignant tumors arising in the ampullary region, which lack approved targeted therapies for their treatment. Methods This retrospective, observational study is based on Secondary Data Use (SDU) previously collected during a multicenter collaboration, which were subsequently entered into a predefined database and analyzed. FoundationOne CDx or Liquid, a next-generation DNA sequencing (NGS) service, was used to identify genomic al...
#1Valeria Merz (University of Verona)H-Index: 10
#2Marina Gaule (University of Verona)H-Index: 4
Last. Davide Melisi (University of Verona)H-Index: 32
view all 13 authors...
Mutations of the proto-oncogene KRAS are the most frequent gain-of-function alterations found in cancer. KRAS is mutated in about 30% of all human tumors, but it could reach more than 90% in certain cancer types such as pancreatic adenocarcinoma. Although historically considered to be undruggable, a particular KRAS mutation, the G12C variant, has recently emerged as an actionable alteration especially in non-small cell lung cancer (NSCLC). KRASG12C and pan-KRAS inhibitors are being tested in cli...
#6Maria Grazia Rodriquenz (Casa Sollievo della Sofferenza)H-Index: 5
OBJECTIVE Germline BRCA1-2 pathogenic variants (gBRCApv) increase the risk of pancreatic cancer and predict for response to platinating agents and poly(ADP-ribose) polymerase inhibitors. Data on worldwide gBRCApv incidence among pancreatic ductal adenocarcinoma (PDAC) patients are sparse and describe a remarkable geographic heterogeneity. The aim of this study is to analyze the epidemiology of gBRCApv in Italian patients. MATERIALS AND METHODS Patients of any age with pancreatic adenocarcinoma, ...
#1Claudio Luchini (University of Verona)H-Index: 33
#2Gaetano Paolino (University of Verona)H-Index: 3
Last. Aldo Scarpa (University of Verona)H-Index: 100
view all 15 authors...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases. The genetic landscape of KRAS wild type PDAC can be divided into three categories. The first is represented by tumors with an activated MAPK pathway due to BRAF mutation that occur in up to 4% of cases. The second includes tumors with microsatellite instability (MSI) due to defective DNA mismatch repair (dMMR), which occurs...
#1Francesca Simionato (University of Verona)H-Index: 14
#2Camilla Zecchetto (University of Verona)H-Index: 10
Last. Davide Melisi (University of Verona)H-Index: 32
view all 34 authors...
Background Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic cancer. However, the risk for positive surgical margins, the poor recovery after surgery that often impairs postoperative treatment, and the common metastatic relapse limit the overall clinical outcomes achieved with this strategy. Polychemotherapeutic combinations are valid options for postoperative treatment in patients with good performance ...
#1Daniela TregnagoH-Index: 7
#2S. ZulianiH-Index: 1
Last. Sara PilottoH-Index: 25
view all 20 authors...
Background: The health emergency caused by the SarS-Cov-2 pandemic has a strong impact on oncological patients’ (pts) life The purpose of this study is to explore the emotional impact and pts’ perception experienced who accessed to our Oncology section at University Hospital and Trust of Verona (Italy) regarding these rules Methods: An questionnaire was designed by our Psycho-Oncology service and administered to all pts accessing to our outpatient facilities during a 21-days period (April 9th - ...
#1Sara MerlerH-Index: 4
#2S. ZulianiH-Index: 1
Last. F. ZacchiH-Index: 1
view all 20 authors...
Background: On February 23rd the first case of SARS-CoV-2 infection was diagnosed at the University Hospital Trust of Verona, Italy On March 13th, the Oncology Section was converted into a 22 inpatient beds COVID unit and we had to reshape our organization and personnel to face the SARS-CoV-2 epidemic, while maintaining our oncological activity Methods: We tracked down oncological activity from January 1st to March 31st, 2020, in relationship to the organizational changes implemented and in comp...
#1Serena Zuliani (University of Verona)H-Index: 2
#2Ilaria Zampiva (University of Verona)H-Index: 6
Last. Francesca Zacchi (University of Verona)H-Index: 2
view all 55 authors...
Abstract Background On February 23rd, the 1st case of SARS-CoV-2 infection was diagnosed at the University Hospital Trust of Verona, Italy. On March 13th, the Oncology Section was converted into a 22-inpatient beds COVID unit and we reshaped our organization to face SARS-CoV-2 epidemic, while maintaining oncological activities. Methods We tracked down: i) volumes of oncological activities (January 1st - March 31st, 2020 versus the same period of 2019), ii) patients' and caregivers' perception, i...
#1Valeria MerzH-Index: 10
#2Camilla ZecchettoH-Index: 10
Last. Davide Melisi (University of Verona)H-Index: 32
view all 19 authors...
Background:Prognosis of patients affected by metastatic esophageal–gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted ...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.